Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

enVVeno Medical Corp

NVNO ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$7.18

▲ +4.44%

Market Cap $4.99M · Vol 5.64K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.99M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

46.95

Momentum

Beta

1.42

vs Market

52W High

$24.50

70.71% below

52W Low

$6.57

9.21% above

Volume

5.64K

Avg 8.38K

P/B

0.01

Price-to-book

ROE

N/A

Return on equity

Free Float

91.92%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, enVVeno Medical Corp (NVNO) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NVNO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.45%

-8.01%

-31.73%

-30.00%

YTD

-36.10%

-71.11%

-95.02%

-97.71%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-19,472,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-52.26% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.01
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	694.83K

Technical Indicators

50-Day SMA	$8.85
200-Day SMA	$10.24
RSI (14)	46.95
Beta	1.42
52-Week High	$24.50
52-Week Low	$6.57

Volume Today	5.64K
Avg Daily Volume (30D)	8.38K
Relative Volume	0.67x
Volatility (10D)	57.52
Volatility (30D)	60.18
Free Float	91.92%

Analyst Consensus

STRONG BUY

Current Price $7.18

Mean Target $30.00

52W Low$6.57 52W High$24.50

Current

Target

$6.57 $24.50

Current Analyst target

+318.12% upside potential · 1 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SRG4B9

ISINUS29415J2050

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateMar 24, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.62% ONC BeOne Medicines AG -1.74% 068270.KS Celltrion, Inc. +5.32% MEDP Medpace Holdings, Inc. +2.37% CRL Charles River Laboratories International, Inc. +3.94%

Company Profile

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.